OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we are working to deliver safe and effective cancer treatments that can provide long-term benefits for patients.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
TAVO™ -- Keynote 695
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):